Kalydeco (Ivacaftor)

Ivacaftor is a CFTR potentiator. It binds to the cystic fibrosis transmembrane conductance regulator protein on the cell surface and increases the likelihood that the chloride channel remains open. This action restores chloride transport across epithelial cells, improving airway surface liquid hydration and overall lung function in patients with gating mutations.

The dosage of Kalydeco is individualized by the prescribing healthcare professional based on the patient’s age, weight, and specific CFTR mutation profile. The prescriber determines the appropriate regimen and any necessary adjustments, so patients should follow the exact instructions provided by their clinician.

Safety data for ivacaftor in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess each case and discuss the risk‑benefit profile with the patient.

To request Kalydeco, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Kalydeco (ivacaftor) is a potentiator that works on specific gating mutations, whereas combination products such as lumacaftor/ivacaftor or tezacaftor/ivacaftor target both gating and processing defects. The choice depends on the patient’s genetic profile, disease severity and prior therapy, with Kalydeco often preferred for isolated gating mutations.

Kalydeco tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and store out of reach of children. Do not refrigerate or freeze the tablets.

Kalydeco is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water. It can be taken with or without food, but consistency with respect to meals is recommended to maintain stable drug levels.

The most serious adverse events reported with ivacaftor include liver injury (elevated transaminases or hepatitis), development of cataracts, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function and visual changes, and any signs of severe rash should prompt immediate medical evaluation.

Kalydeco is contraindicated in patients with known hypersensitivity to ivacaftor or any of the tablet excipients. Caution is advised for individuals with severe liver disease, as they may be at higher risk for hepatic adverse effects. Patients should discuss their full medical history with a healthcare professional before starting therapy.